# US 2021/0371403 A1 · Small molecules targeting mutant mammalian proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0371403 A1
- Document ID: US20210371403A1
- Status: Published application
- Kind: A1
- Application number: 17/278,043
- Filed: 2019-09-20
- Published: 2021-12-02
- Earliest claimed: 2018-09-21
- Assignees: Jnana Therapeutics Inc.
- Applicants: Jnana Therapeutics, Inc.
- Inventors: Giovanni Muncipinto; Lyn H. Jones; Terry J. Rettenmaier; John A. Malona
- Web page: https://patentgrep.com/patent/US20210371403A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07C 279/10: being further substituted by doubly-bound oxygen atoms
- C07D 213/56: Amides
- C07D 213/57: Nitriles
- C07D 213/64: attached in position 2 or 6
- C07D 229/02: containing three-membered rings
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/24: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 235/02: condensed with carbocyclic rings or ring systems
- C07D 239/16: acylated on said nitrogen atoms
- C07D 239/22: with hetero atoms directly attached to ring carbon atoms
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/07: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 307/14: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 307/54: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 317/46: condensed with one six-membered ring
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 495/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

## Claims

### Claim 1

A compound of Formula (I) or (II):
wherein
X, Y, W, and Z are independently selected from N and C(R); provided that no more than two of X, Y, W, and Z are N;
if Z and W, or W and Y, or Y and X are C(R), then any two adjacent instances of R taken together may form a fused 3-8 membered ring;
Q is OH, —NHSO2R′, —COOH, —C(O)NHSO2R″, —SO2NHC(O)R″, tetrazolyl, or —CRxRyOH;
R is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-heteroaryl, haloalkyl, halocycloalkyl, halocycloheteroalkyl, —O-alkyl, —O-haloalkyl, —O-cycloalkyl, —N-alkyl, —N-haloalkyl, —N-cycloalkyl, —S-alkyl, —S-haloalkyl, —S-cycloalkyl, —O-heteroalkyl, —O-cycloheteroalkyl, —N-heteroalkyl, —N-cycloheteroalkyl, —S-heteroalkyl, —S-cycloheteroalkyl, —O-aryl, —N-aryl, —S-aryl, —O-heteroaryl, —N-heteroaryl, —S-heteroaryl, substituted or unsubstituted —O-alkylene-aryl, substituted or unsubstituted —N-alkylene-aryl, substituted or unsubstituted —S-alkylene-aryl, substituted or unsubstituted —O-alkylene-heteroaryl, substituted or unsubstituted —N-alkylene-heteroaryl, substituted or unsubstituted —S-alkylene-heteroaryl, halide, —CN, —NO2, —S(O)Ra, —S(O)2Ra, —C(O)Ra, —C(O)2Ra, —C(O)NRaRb, OH, and C(O)NR′C(NR′)NRaRb;
R′ is H, alkyl, or aryl;
R″ is alkyl or aryl;
Ra and Rb are independently H, alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, cycloalkyl, heteroalkyl, haloalkyl, cycloheteroalkyl, halocycloalkyl, halocycloheteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted -alkylene-heteroaryl or Ra and Rb taken together with the nitrogen atom to which they are attached may form a 3-8 membered ring;
R1 is
R2, R3, R4, and R5 are independently selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, haloalkyl, halocycloalkyl, cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-heteroaryl, substituted or unsubstituted 5-12 membered ring, alkylenealkoxy, haloalkyl, —CN, —C(O)Ra, and —C(O)NRaRb; provided that (i) no more than one of R2, R3, R4, and R5 is —CN, (ii) no more than one of R2, R3, R4, and R5 is —C(O)Ra, and (iii) no more than one of R2, R3, R4, and R5 is —C(O)NRaRb;
R3 and R4 taken together may form a 5-8 membered ring;
R2 and R5 taken together may form a 5-8 membered ring;
R4 and R5 taken together may form a 5-8 membered ring;
Rc is H, or alkyl;
Rd and Re are independently absent, H, or alkyl;
Rx and Ry are independently H, F, alkyl, aryl, or haloalkyl;
represents a single bond or a double bond; if is a double bond, then Rd and Re are absent;
A is absent, —CH2—, —C(O)—, —C(S)—, —S(O)2—, or —CRfRg—;
X′ is absent, —CH2—, —C(O)—, —C(S)—, or —S(O)2—; and
Rf and Rg are independently selected from H, alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted -alkylene-heteroaryl, and halide; or Rf and Rg taken together may form a spirocyclic 3-8 membered ring, or heterospirocyclic 3-8 membered ring.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is
and R3 is H.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim 9

A compound of Formula (III):
wherein:
R6 is selected from H, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-heteroaryl, haloalkyl, halocycloalkyl, halocycloheteroalkyl, —O-alkyl, —O-haloalkyl, —O-cycloalkyl, —N-alkyl, —N-haloalkyl, —S-alkyl, —O-heteroalkyl, —N-heteroalkyl, —S-heteroalkyl, —O-aryl, —N-aryl, —S-aryl, —S-haloalkyl, —S-cycloalkyl, —O-heteroaryl, —O-cycloheteroalkyl, —N-heteroaryl, —N-cycloalkyl, —N-cycloheteroalkyl, —S-cycloheteroalkyl, —S-heteroaryl, halide, —CN, —NO2, —S(O)Ra, —S(O)2Ra, —C(O)Ra, —C(O)2Ra, and —C(O)NRaRb;
Ra and Rb are independently H, alkyl, alkenyl, alkynyl substituted or unsubstituted aryl, cycloalkyl, heteroalkyl, haloalkyl, cycloheteroalkyl, halocycloalkyl, halocycloheteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted -alkylene-heteroaryl or Ra and Rb taken together with the nitrogen atom to which they are attached may form a 3-8 membered ring;
R7 is H, halide, alkyl, or aryl;
R8 is
and
R9 is selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, haloalkyl, halocycloalkyl, cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted -alkylene-aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -alkylene-heteroaryl, —CN, —C(O)Ra, and —C(O)NRaRb.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R6 is selected from halide, —CN, —CF3, —OCF3, —SO2Me, and —NO2.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R6 is halide.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R6 is Cl, F, or Br.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R6 is —CN.

### Claim 14 (depends on 10)

The compound of claim 10, wherein R6 is —CF3.

### Claim 15 (depends on 10)

The compound of claim 10, wherein R6 is —OCF3.

### Claim 16 (depends on 10)

The compound of claim 10, wherein R6 is —SO2Me.

### Claim 17 (depends on 10)

The compound of claim 10, wherein R6 is —NO2.

### Claim 18 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 9-17, wherein R7 is H.

### Claim 19 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 9-17, wherein R7 is halide.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R7 is Cl or F.

### Claim 21 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 9-17, wherein R7 is alkyl.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R7 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R7 is methyl.

### Claim 24 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 9-17, wherein R7 is aryl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R7 is phenyl.

### Claim 26 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 9-25, wherein R8 is

### Claim 27 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 9-25, wherein R8 is

### Claim 28 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 9-25, wherein R8 is

### Claim 29 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is H.

### Claim 30 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is alkyl.

### Claim 31 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is unsubstituted heteroaryl.

### Claim 32 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is alkylene-aryl.

### Claim 33 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is alkylene-heteroaryl.

### Claim 34 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is alkylene-CF3.

### Claim 35 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is alkylene-OMe.

### Claim 36 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 9-28, wherein R9 is 5-12 membered ring.

### Claim 37 (depends on 9)

The compound of claim 9, wherein the compound is selected from:

### Claim 38 (depends on 9)

The compound of claim 9, wherein the compound is

### Claim 39 (depends on 9)

The compound of claim 9, wherein the compound is selected from:

### Claim 40 (depends on 1)

The compound of claim 1, wherein the compound is selected from:

### Claim 41 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 42 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 43 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 44 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 45 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 46 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 47 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 48 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 49 (depends on 1)

The compound of claim 1, wherein the compound is selected from

### Claim 50 (depends on 1)

The compound of claim 1, wherein the compound is

### Claim 51 (depends on 1)

The compound of claim 1, wherein the compound is selected from the following table:

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A pharmaceutical composition, comprising a compound of any one of claims 1-51; and a pharmaceutical acceptable excipient.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method of treating or preventing a disease or disorder associated with a SLC6A8 mutation, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-51.

### Claim 54 (depends on 53)

The method of claim 53, wherein the disease or disorder is creatine transporter deficiency.

### Claim 55 (depends on 53)

The method of claim 53, wherein the disease or disorder is motor dysfunction.

### Claim 56 (depends on 53)

The method of claim 53, wherein the disease or disorder is intellectual disability.

### Claim 57 (depends on 53)

The method of claim 53, wherein the disease or disorder is language delay or speech delay.

### Claim 58 (depends on 53)

The method of claim 53, wherein the disease or disorder is hypotonia.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method of improving function of a cellular creatine transporter, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-51.

### Claim 60 (depends on 59)

The method of claim 59, wherein the creatine transporter is SLC6A8.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, wherein the creatine transporter is a mutant creatine transporter.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a cell, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any one of claims 1-51.

### Claim 63 (depends on 62)

The method of claim 62, wherein the compound decreases intracellular accumulation of guanidinoacetic acid or a salt thereof.

### Claim 64 (depends on 62)

The method of claim 62, wherein the compound decreases the intracellular concentration of guanidinoacetic acid or a salt thereof.

### Claim 65 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the mutant creatine transporter is mutant SLC6A8.

### Claim 66 (depends on 62, 63, 64, 65)

The method of any one of claims 62-65, wherein the cell is a brain cell.

### Claim 67 (depends on 62, 63, 64, 65, 66)

The method of any one of claims 62-66, wherein the mammal is a male.

### Claim 68 (depends on 62, 63, 64, 65, 66)

The method of any one of claims 62-66, wherein the mammal is a female.

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 62-68, wherein the mammal is a primate, equine, bovine, ovine, feline, or canine.

### Claim 70 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 62-68, wherein the mammal is a human.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any one of claims 1-51.

### Claim 72 (depends on 71)

The method of claim 71, wherein the mutant creatine transporter is mutant SLC6A8.

### Claim 73 (depends on 71, 72)

The method of claim 71 or 72, wherein the mammal is a male.

### Claim 74 (depends on 71, 72)

The method of claim 71 or 72, wherein the mammal is a female.

### Claim 75 (depends on 71, 72, 73, 74)

The method of any one of claims 71-74, wherein the mammal is a primate, equine, bovine, ovine, feline, or canine.

### Claim 76 (depends on 71, 72, 73, 74)

The method of any one of claims 71-74, wherein the mammal is a human.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A method of treating an inflammatory disease, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any one of claims 1-51.

### Claim 78 (depends on 77)

The method of claim 77, wherein the inflammatory disease is acute.

### Claim 79 (depends on 77)

The method of claim 77, wherein the inflammatory disease is chronic.

### Claim 80 (depends on 77, 78, 79)

The method of any one of claims 77-79, wherein the inflammatory disease is selected from inflammatory bowel diseases (for example, ulcerative colitis or Crohn's disease), multiple sclerosis, psoriasis, arthritis, rheumatoid arthritis, osteoarthritis, juvenile arthritis, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, cryopyrin associated periodic syndromes, Muckle-Wells syndrome, familial cold auto-inflammatory syndrome, neonatal-onset multisystem inflammatory disease, TNF receptor associated periodic syndrome, acute and chronic pancreatitis, atherosclerosis, gout, ankylosing spondylitis, fibrotic disorders (for example, hepatic fibrosis or idiopathic pulmonary fibrosis), nephropathy, sarcoidosis, scleroderma, anaphylaxis, diabetes (for example, diabetes mellitus type 1 or diabetes mellitus type 2), diabetic retinopathy, Still's disease, vasculitis, sarcoidosis, pulmonary inflammation, acute respiratory distress syndrome, wet and dry age-related macular degeneration, autoimmune hemolytic syndromes, autoimmune and inflammatory hepatitis, autoimmune neuropathy, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant associated autoimmune disease, Sjogren's syndrome, familial Mediterranean fever, systemic lupus erythematosus, vasculitis syndromes (for example, temporal, Takayasu's and giant cell arteritis, Behçet's disease or Wegener's granulomatosis), vitiligo, secondary hematologic manifestation of autoimmune diseases (for example, anemias), drug-induced autoimmunity, Hashimoto's thyroiditis, hypophysitis, idiopathic thrombocytic pupura, metal-induced autoimmunity, myasthenia gravis, pemphigus, autoimmune deafness (for example, Meniere's disease), Goodpasture's syndrome, Graves' disease, HW-related autoimmune syndromes, Gullain-Barre disease, Addison's disease, anti-phospholipid syndrome, asthma, atopic dermatitis, Celiac disease, Cushing's syndrome, dermatomyositis, idiopathic adrenal adrenal atrophy, idiopathic thrombocytopenia, Kawasaki syndrome, Lambert-Eaton Syndrome, pernicious anemia, pollinosis, polyarteritis nodosa, primary biliary cirrhosis, primary sclerosing cholangitis, Raynaud's, Reiter's Syndrome, relapsing polychondritis, Schmidt's syndrome, thyrotoxidosis, sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, toxic shock syndrome, glomerulonephritis, peritonitis, interstitial cystitis, hyperoxia-induced inflammations, chronic obstructive pulmonary disease (COPD), vasculitis, graft vs. host reaction (for example, graft vs. host disease), allograft rejections (for example, acute allograft rejection or chronic allograft rejection), early transplantation rejection (for example, acute allograft rejection), reperfusion injury, pain (for example, acute pain, chronic pain, neuropathic pain, or fibromyalgia), chronic infections, meningitis, encephalitis, myocarditis, gingivitis, post surgical trauma, tissue injury, traumatic brain injury, enterocolitis, sinusitis, uveitis, ocular inflammation, optic neuritis, gastric ulcers, esophagitis, peritonitis, periodontitis, dermatomyositis, gastritis, myositis, polymyalgia, pneumonia and bronchitis.

### Claim 81 (depends on 77, 78, 79, 80)

The method of any one of claims 77-80, wherein the mammal is a male.

### Claim 82 (depends on 77, 78, 79, 80)

The method of any one of claims 77-80, wherein the mammal is a female.

### Claim 83 (depends on 77, 78, 79, 80)

The method of any one of claims 77-80, wherein the mammal is a primate, equine, bovine, ovine, feline, or canine.

### Claim 84 (depends on 77, 78, 79, 80)

The method of any one of claims 77-80, wherein the mammal is a human.
